NCT06774690 Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study
| NCT ID | NCT06774690 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | HCC - Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,300 participants |
| Start Date | 2021-04-21 |
| Primary Completion | 2030-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,300 participants in total. It began in 2021-04-21 with a primary completion date of 2030-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn what are the best conditions that will give a positive outcome to men and women that receive a intra arterial therapy (IAT) for primary liver cancer. Intra arterial therapies are radiologic procedures that block liver cancer blood supply. The researchers will collect the data of participants located in the Radiology department in "IRCCS Azienda Ospedaliera Universitaria" Hospital in Bologna and will study clinic and radiological traits to understand which is the best case scenario for a optimal treatment response.
Eligibility Criteria
Inclusion Criteria: * diagnosis of Hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA) and clinical indication to receive or have already received one of the following treatments: * Trans-arterial embolization (TAE), * Transarterial chemoembolization (TACE), * Transarterial radioembolization (TARE) * Drug-eluting beads chemoembolization (DEB-TACE) * Age over 18 * To give informed consent Exclusion Criteria: * shunt of gastro intestinal arteries that cannot be embolized * metastasis spread outside of the liver * liver failure
Contact & Investigator
Cristina Mosconi, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06774690 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HCC - Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06774690 currently recruiting?
Yes, NCT06774690 is actively recruiting participants. Contact the research team at cristina.mosconi@aosp.bo.it for enrollment information.
Where is the NCT06774690 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06774690 clinical trial?
NCT06774690 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Cristina Mosconi, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 3,300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.